Skip to main content
SpringerLink
Log in

Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Koshy M, Dorn L, Bressler L, Molokie R, Lavelle D, Talischy N, Hoffman R, van Overveld W, DeSimone J (2000) 2-deoxy 5-azacitidine and fetal hemoglobin induction in sickle cell anemia. Blood 96(7):2379–2384

    Article  CAS  Google Scholar 

  2. Baz W, Najfeld V, Yotsuya M, Talwar J, Terjanian T, Forte F (2012) Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia. Clin Med Insights Oncol 6:149–152

    Article  CAS  Google Scholar 

  3. Aumont C, Driss F, Lazure T, Picard V, Creidy R, De Botton S, Saada V, Lambotte O, Bilhou-Nabera C, Tertian G, Michot JM (2015) Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia. Am J Hematol 90(7):E131–E132

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine Department, Sickle Cell Referral Center, Georges Pompidou European Hospital, AP-HP, Paris, France

    Gonzalo De Luna, Jacques Pouchot & Jean-Benoît Arlet

  2. Université de Paris, Paris, France

    Gonzalo De Luna, Luc Darnige, Jacques Pouchot & Jean-Benoît Arlet

  3. Service d’Hématologie Biologique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France

    Luc Darnige

  4. INSERM UMR-S1140, Paris, France

    Luc Darnige

  5. Nephrology Department, Georges Pompidou European Hospital, AP-HP, INSERM, Paris, France

    Stéphane Roueff

  6. Département Centre National de Référence pour les Groupes Sanguins (CNRGS), Institut National de la Transfusion Sanguine (INTS), 75011, Paris, France

    Thierry Peyrard

  7. Laboratory of Excellence GR-Ex, Paris, France

    Thierry Peyrard & Jean-Benoît Arlet

  8. Service de Médecine Interne, Hôpital européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France

    Jean-Benoît Arlet

Authors
  1. Gonzalo De Luna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luc Darnige
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stéphane Roueff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thierry Peyrard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jacques Pouchot
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jean-Benoît Arlet
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JBA, GDL, and JP drafted the manuscript; LD performed the bone marrow aspirations and their analysis; TP managed the transfusional aspects, LD, TP, and SR participated in the critical analysis of the results; all authors have approved the manuscript.

Corresponding author

Correspondence to Jean-Benoît Arlet.

Ethics declarations

Conflict of interest

The authors declare that they have no competing financial interests.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the patients included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Luna, G., Darnige, L., Roueff, S. et al. Usefulness of azacitidine therapy in a sickle cell disease patient with myelodysplastic syndrome. Ann Hematol 99, 661–662 (2020). https://doi.org/10.1007/s00277-020-03940-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-020-03940-8

Search

Navigation